Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.65 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.50 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10274847 | 0.84 | NOTUM (0.65) | NOTUMPDE3BPDE3AKMT2APOLB | |
| SCHEMBL594255 | 0.83 | NOTUM (0.63) | NOTUMPDE3BPDE3AKMT2APOLB | |
| SCHEMBL395823 | 0.83 | NOTUM (0.63) | NOTUMPDE3BPDE3AKMT2APOLB | |
| Hydrochloric Acid SCHEMBL398436 | 0.82 | NOTUM (0.61) | NOTUMPDE3BPDE3AKMT2APOLB | |
| SCHEMBL6985785 | 0.81 | KMT2A (0.60) | NOTUMPDE3BPDE3AKMT2APOLB | |
| SCHEMBL18737439 | 0.81 | NOTUM (0.60) | NOTUMPDE3BPDE3AKMT2APOLB | |
| SCHEMBL14771955 | 0.81 | NOTUM (0.60) | NOTUMPDE3BPDE3AKMT2APOLB | |
| SCHEMBL13165250 | 0.81 | NOTUM (0.60) | NOTUMPDE3BPDE3AKMT2APOLB | |
| SCHEMBL25386717 | 0.80 | NOTUM (0.58) | NOTUMPDE3BPDE3AKMT2APOLB | |
| SCHEMBL6392940 | 0.80 | NOTUM (0.58) | NOTUMPDE3BPDE3AKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605468-B2 | Oxazine-based fluorophore compounds for nerve-specific imaging | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2026-04-21 | — | — | US | disclosed |
| US-20230148317-A1 | OXAZINE-BASED FLUOROPHORE COMPOUNDS FOR NERVE-SPECIFIC IMAGING | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230148317-A1 | OXAZINE-BASED FLUOROPHORE COMPOUNDS FOR NERVE-SPECIFIC IMAGING | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4093443-A1 | OXAZINE-BASED FLUOROPHORE COMPOUNDS FOR NERVE-SPECIFIC IMAGING | Oregon Health & Science University (US) | 2022-11-30 | — | — | EP | disclosed |
| US-11492359-B2 | Near-infrared nerve-sparing fluorophores | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-11-08 | — | — | US | disclosed |
| CN-115279423-A | Oxazine-based fluorophore compounds for neurospecific imaging | 俄勒冈健康与科学大学 | 2022-11-01 | — | — | CN | disclosed |
| US-20210317137-A1 | NEAR-INFRARED NERVE-SPARING FLUOROPHORES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210236657-A1 | NERVE-SPECIFIC FLUOROPHORE FORMULATIONS FOR DIRECT AND SYSTEMIC ADMINISTRATION | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210236657-A1 | NERVE-SPECIFIC FLUOROPHORE FORMULATIONS FOR DIRECT AND SYSTEMIC ADMINISTRATION | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2021-08-05 | — | — | US | disclosed |
| WO-2021150979-A1 | OXAZINE-BASED FLUOROPHORE COMPOUNDS FOR NERVE-SPECIFIC IMAGING | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2021-07-29 | — | — | WO | disclosed |
| EP-3833401-A1 | NERVE-SPECIFIC FLUOROPHORE FORMULATIONS FOR DIRECT AND SYSTEMIC ADMINISTRATION | Oregon Health & Science University (US) | 2021-06-16 | — | — | EP | disclosed |
| WO-2020033435-A1 | NERVE-SPECIFIC FLUOROPHORE FORMULATIONS FOR DIRECT AND SYSTEMIC ADMINISTRATION | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020023911-A2 | NEAR-INFRARED NERVE-SPARING FLUOROPHORES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2020-01-30 | — | — | WO | disclosed |
| CN-100349897-C | Substituted amino isoxazoline derivatives and their use as anti-depressants | JANSSEN PHARMACEUTICA NV (BE) | 2007-11-21 | — | — | CN | disclosed |
| EP-1492796-B1 | SUBSTITUTED AMINO ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS. | JANSSEN PHARMACEUTICA NV (BE) | 2007-09-05 | — | — | EP | disclosed |
| US-7265103-B2 | Substituted amino isoxazoline derivatives and their use as anti-depressants | JANSSEN PHARMACEUTICA NV. (BE) | 2007-09-04 | — | — | US | disclosed |
| US-20050222125-A1 | Substituted amino isoxazoline derivatives and their use as anti-depressants | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-06 | — | — | US | disclosed |
| CN-1642960-A | Substituted amino isoxazoline derivatives and their use as anti-depressants | JANSSEN PHARMACEUTICA NV (BE) | 2005-07-20 | — | — | CN | disclosed |
| EP-1492796-A1 | SUBSTITUTED AMINO ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS. | Janssen Pharmaceutica N.V. (BE) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082878-A1 | SUBSTITUTED AMINO ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS. | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492359-B2 | Near-infrared nerve-sparing fluorophores | NTRK1, PMP22, GAP43 | NOTUM 2857/4885PDE3B 1526/4885PDE3A 846/4885 |
| US-20210236657-A1 | NERVE-SPECIFIC FLUOROPHORE FORMULATIONS FOR DIRECT AND SYSTEMIC ADMINISTRATION | PFAS, NPFFR2, NPFFR1 | NOTUM 2200/4885PDE3B 2517/4885PDE3A 2348/4885 |
| US-20230148317-A1 | OXAZINE-BASED FLUOROPHORE COMPOUNDS FOR NERVE-SPECIFIC IMAGING | GAP43, NTRK1, CHAT | NOTUM 2873/4885PDE3B 2705/4885PDE3A 2146/4885 |
| US-12605468-B2 | Oxazine-based fluorophore compounds for nerve-specific imaging | CHRNB2, CHRNB3, CHRNB4 | NOTUM 4151/4885PDE3B 2729/4885PDE3A 2280/4885 |
| US-20050222125-A1 | Substituted amino isoxazoline derivatives and their use as anti-depressants | HTR2C, HTR7, HTR1A | NOTUM 4497/4885PDE3B 831/4885PDE3A 1042/4885 |
| US-20210317137-A1 | NEAR-INFRARED NERVE-SPARING FLUOROPHORES | NTRK1, NGF, SMN1; SMN2 | NOTUM 2998/4885PDE3B 1084/4885PDE3A 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.